Pharmaceutical Value proposition
AbbVie is a global biopharmaceutical company focused on creating medicines and solutions that put impact first — for patients, communities, and our world. We aim to address complex health issues and enhance people's lives through our core therapeutic areas: immunology, oncology, neuroscience, eye care, aesthetics and other areas of unmet need.
Learn more about us at www.abbvie.com and review our community guidelines at https://www.abbvie.com/social-media-community-guidelines.html.
Biopharmaceutical, Biotechnology, Innovation, Research and Development, Manufacturing, Biotherapeutics, Oncology, Immunology, Virology, Neuroscience, Womens Health, Aesthetics, and Eye Care
Pharmaceutical Research & Development | AbbVie
Pharmaceutical Research & Development | AbbVie
https://www.abbvie.com/
| Entity | Type | Tweets | Articles | |
|---|---|---|---|---|
 | AI Fund Venture Capital and Private Equity Principals | Other 25 Mar 2025 | | |
 | DASTRI Environmental Services, greentech, cleantech | Other 23 Mar 2025 | | |
 | Senti Biosciences Biotechnology Research, biotech, deeptech | Other 31 Jan 2025 | | |
 | ALE | Atlantic Lab Equipment Inc. Biotechnology Research, biotech, deeptech | Other 4 Mar 2025 | | |
 | Inato biotech, Technology, Information and Internet, deeptech | Other 19 Mar 2025 | | |
 | NETRI Biotechnology Research, biotech, deeptech | Other 17 Mar 2025 | | |
 | MedicoTech - OncoClic Software Development, healthtech, deeptech | Other 5 Mar 2025 | | |
 | AdBio partners | Other 10 Feb 2025 | | |
 | Stifterverband Think Tanks, it services | Other 3 Mar 2025 | | |
 | PhoreMost Ltd Biotechnology Research, biotech, deeptech | Other 28 Feb 2025 | | |
🎉 Wir gratulieren PHAME Therapeutics zum Golden Ticket! 🎉
Innovationen fördern, die Forschung vorantreiben und die Region unterstützen – genau dafür stehen unsere Partnerschaft mit BioLabs Heidelberg und unser Golden-Ticket-Programm.
Niels Emmerich und Joachim Vogt haben gestern das Golden Ticket übergeben. Das Gewinner-Team von PHAME, eine Ausgründung aus dem Heidelberger Max-Planck-Institut für medizinische Forschung, erhält damit ein Jahr kostenlosen Zugang zu modernster Laborinfrastruktur im BioLabs-Inkubator Heidelberg. Zusätzlich unterstützen unsere AbbVie-Forschungsteams das Projekt mit ihrer umfassenden Expertise.
PHAME entwickelt eine Technologie zur Entdeckung von Antikörpern, die gezielt an GPCR-Proteine binden und diese modulieren – GPCRs spielen in zahlreichen onkologischen, immunologischen und neurologischen Erkrankungen eine zentrale Rolle.
Herzlichen Glückwunsch an Konstantin Hinnah, Kai Johnsson und das gesamte PHAME-Team! Wir sind gespannt auf die gemeinsame Reise und freuen uns, euch auf eurem Weg zu begleiten!
💡 Das nächste Golden Ticket ist übrigens schon in Planung. Ihr dürft gespannt sein...
#Innovation #Forschungsförderung #GoldenTicket
Ahead of World Cancer Day, some of our oncology leaders reflect on what drives their passions to transform outcomes for cancer patients. Learn more about our work in oncology: https://bit.ly/4jBxDVR
#WorldCancerDay #Oncology #CancerAwareness #CancerSupport #TogetherAgainstCancer
Breakthroughs take all of us. Make your mark by helping improve lives around the world through your work. Discover your next role: https://bit.ly/3E6htnn
NEWS: We've entered a partnership with Neomorph, Inc. to develop novel molecular glue degraders for multiple targets across #oncology and #immunology. Learn more: https://bit.ly/4hqmwgH
Nimble Therapeutics is now part of AbbVie. This #acquisition expands our pipeline with a novel approach in #psoriasis and enhances our R&D capabilities with a propriety platform technology. Learn more: https://bit.ly/4g5KjkN $ABBV
[Video description: On-screen text reads, “Nimble Therapeutics is now part of AbbVie” followed by the AbbVie and Nimble Therapeutics logos.]